Abstract
Squamous cell carcinoma (SCC) is the most commonly diagnosed oral cancer. It is a type of head and neck squamous cell carcinoma (HNSCC) oral cancer affects more than 300,000 people in a year. Oral cancer is the sixth most common malignant cancer. The traditional methods of treatment were used through surgery, followed by chemotherapy, but these methods are not effective enough for the treatment, so treatment was focused on using magnetic nanoparticles. Magnetic nanoparticles demolish only the cancer cells directly without affecting healthy cells. They can also be used to increase the effectiveness of the other treatment methods. Iron oxide nanoparticles, maghemite (Fe2O3) and magnetite (Fe3O4) are widely used in the diagnosis and treatment of cancerous diseases. Iron oxides NPs have distinctive properties as they have good biodegradability, very low toxicity, modifiability, and ease of preparation. the method of hyperthermia is one of the effective methods in the treatment of cancer. Because cancer cells show greater sensitivity to high temperature compared to normal cells.
Publisher
Izmir International Guest Student Association
Reference62 articles.
1. 1. Arruebo, M., et al., Chem. Mater. Nanoscience Institute of Aragon (INA), Pedro Cerbuna 12, University of Zaragoza, 50009 Zaragoza, Spain *E-mail: iqcatal@unizar.es (2006) 18, 1911.
2. 2. C. Alexiou, R. Jurgons, R.J. Schmid, C. Bergemann, J. Henke, W. Erhardt, et al., Magnetic drug targeting- biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment, J. Drug Target. 11 (3) (2003) 139-149.
3. 3. C. Alexiou, R.J. Schmid, R. Jurgons, M. Kremer, G. Wanner, C. Bergemann, et al., Targeting cancer cells: magnetic nanoparticles as drug carriers, Eur. Biophys. J. 35 (5) (2006) 446-450 (Epub 2006 January 31).
4. 4. P. Ashtari, X. He, K. Wang, P. Gong, Talanta 67, 548 (2005). doi:10.1016/j.talanta.2005.06.043
5. 5. Bandyopadhyay A, Raghavan S. Defining the role of integrin alpha v beta 6 in cancer. Curr Drug Targets. 2009;10(7):645‐652.